Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: Results from the palivizumab outcomes registry

Pediatric Pulmonology

Volumn 35, Issue 6, 2003, Pages 484-489

  Boron, Marnie ^a  

^a MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB; PLACEBO;

ARTICLE; ARTIFICIAL VENTILATION; CHRONIC LUNG DISEASE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GESTATIONAL AGE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INFANT; LOWER RESPIRATORY TRACT INFECTION; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; FEMALE; HOSPITALIZATION; HUMANS; INFANT; MALE; PROSPECTIVE STUDIES; REGISTRIES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK FACTORS; TREATMENT OUTCOME;

EID: 0038350757     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.10288     Document Type: Article

References (12)

1. Shay DK, Holman RC, Newman RD, Liu LL, Stout W, Anderson JW. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999;282:1440-1446.
2. Prober CG, Sullender WM. Advances in prevention of respiratory syncytial virus infections. J Pediatr 1999;135:546-558.
3. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986;140:543-546.
4. Hall CB. Respiratory syncytial virus: what we know now. Contemp Pediatr 1993;10:2-11.
5. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis 2001;183:16-22.
6. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial infection in high-risk infants. Pediatrics 1998;102:531-537.
7. Sorrentino M, Powers T, Palivizumab Outcomes Study Group. Effectiveness of palivizumab: evaluation of outcomes from the 1998-1999 respiratory syncytial virus season. Pediatr Infect Dis J 2000;19:1068-1071.
8. Cohen AH, Sorrentino M, Powers T. Effectiveness of palivizumab for preventing serious RSV disease. J Respir Dis Pediatr [Suppl] 2000;2:30-32.
9. American Academy of Pediatrics, Committee on Infectious Diseases. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998;102:1211-1216.
10. Carbonell-Estrany X, Quero J, IRIS Study Group. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J 2001; 20:874-879.
11. Carbonell-Estrany X, Quero J, Bustos G, et al. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. Pediatr Infect Dis J 2000;19:592-597.
12. Centers for Disease Control. Update. Respiratory syncytial virus activity - United States, 1998-1999 season. MMWR 1999;48: 1104-1106, 1115.